ArticleESMO open2023
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Article in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Assessing Quality Gaps and Clinician Perspectives on AI Integration in Colorectal Cancer NGS Pathways.Current oncology (Toronto, Ont.) · 2026Article
- What's new in neoplastic pulmonary pathology 2026: updates on grading, staging and molecular testing.Journal of pathology and translational medicine · 2026Article
- Standardized protocols for reflexing to a multigene panel for patients with non-small cell lung cancer: prevalence and perceived barriers to comprehensive, pathologist-ordered biomarker reflex testing.American journal of clinical pathology · 2026Article
- HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients.Targeted oncology · 2026Article
- Review
- Evidence-Based Laboratory Testing Algorithms: A Strategic Approach to Improving Diagnostic Accuracy.Cureus · 2026Review
- Integration of ROSE cytology and serum tumor markers for rapid subtyping of lung cancer.Scientific reports · 2025Article
- Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals.Future oncology (London, England) · 2025Article
- Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand.Translational lung cancer research · 2025Review
- Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.JTO clinical and research reports · 2025Article
- Optimization of oncology biomarker testing in managed care: Best practices and consensus recommendations from an AMCP Market Insights program.Journal of managed care & specialty pharmacy · 2025Article
- Prevalence ofTranslational lung cancer research · 2025Article
- Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.The oncologist · 2025Review
- Results of a modified Delphi consensus on the optimal testing pathway for oesophago-gastric cancer care in the UK.BMJ open · 2025Article
- [Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].Magyar onkologia · 2024Article
- Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum.Current oncology (Toronto, Ont.) · 2024Review
- Next step of molecular pathology: next-generation sequencing in cytology.Journal of pathology and translational medicine · 2024Review
- Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays the start of first-line systemic treatment, which is crucially informed by the results of such analysis. Reflex testing, in which the responsibility for testing for an agreed range of biomarkers lies with the pathologist, has been shown to standardise and expedite the process. Twelve experts discussed the rationale and considerations for implementing reflex testing as standard clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.